Cytokinetics (CYTK) Tops Q4 EPS by 8c
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $86.50 +5.24%
Revenue Growth %: -75.4%
Financial Fact:
Total revenues: 59.05M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Revenue Growth %: -75.4%
Financial Fact:
Total revenues: 59.05M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of ($0.24), $0.08 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $10.49 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Upgrades Cytokinetics (CYTK) to Buy
- Bernstein SocGen on UnitedHealth Group (UNH): 'Expecting a strong 2Q driven by MA and potential for guidance raise'
- Palantir surges 4% on Nvidia sovereign AI pact as software beats semis
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
